12Jan
09Jan
When ‘time is brain’
...Now Lechleiter and his teammates at Astrocyte Pharmaceuticals — to which UT Health San Antonio has given exclusive licensing rights to develop the drug — are preparing for phase 2 clinical trials. These trials will focus on evaluating the effectiveness of AST-004 in reducing brain tissue loss in patients with large occlusion strokes, a severe type of stroke where blood clots cause substantial brain damage. Read more >>
09Jan
🍾 HAPPY NEW YEAR 2025 🍾 BOSTON HARBOR ANGELS ENTERS ITS 3RD DECADE OF ANGEL INVESTING
A happy new year to all founders, angels, and everyone else that plays a part in this ecosystem. Boston Harbor Angels wishes them a successful 2025 and upcoming decade! Boston Harbor Angels now enters its 3rd decade of angel investing, helping support and fund great founders, entrepreneurs, and companies. Founded in 2004, Boston Harbor Angels has created an interconnected community and ecosystem of investors, founders and mentors. Boston Harbor Angels is dedicated to helping founders weather the tumultuous battle that...
09Jan
Manufacturing startup tops growth charts, secures major funding
Reflecting back on 2024 for a moment, one Buffalo startup in particular had quite a year. That's why Buffalo Business First put CleanFiber among its 10 honored companies of the year in 2024. This local business is getting national recognition and securing major funding — from right here in Western New York. To say 2024 has been a banner year for Blasdell startup CleanFiber would be an understatement. CleanFiber was the only local company to break into the top 50...
09Jan
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
Corbus Pharmaceuticals Holdings, Inc., today announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom (“Western study”) of CRB-701 (SYS6002) will be presented at the 2025American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), to be held in San Francisco, CA February 13–15, 2025. The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid...
07Jan
EXCLUSIVE: 2025 vision tech trends
Roland Mattern, Director of Sales at eSight by Gentex Corporation, discusses some of the key vision technology trends that will shape 2025 and give people greater independence and inclusivity across various aspects of life. Modern technology continues to change every aspect of human life and vision technology is no different. More than two million people in the UK have some degree of visual impairment or sight loss and nearly half of these people have a long-term, irreversible eye health condition....
04Jan
LPOXY Therapeutics, Inc. Acquires Key Assets from Xeno Biosciences Inc. to Advance C. difficile Prevention Therapy
LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced today that it has signed a term sheet to acquire selected assets from Xeno Biosciences Inc. The assets include regulatory filings, correspondence, and documentation from FDA and global regulatory interactions, as well as comprehensive CMC data. LPOXY will benefit from ownership of data generated in Xeno's Phase I and Ib clinical trials, which validates the safety of the Active Pharmaceutical Ingredient shared by Xeno's...
04Jan